{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:44:28Z","timestamp":1785840268276,"version":"3.56.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100021332","name":"Honor Society of Phi Kappa Phi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011862","name":"University of North Carolina at Greensboro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011862","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immune checkpoint inhibitors (ICIs)have significantly improved overall survival rates in many aggressive cancers. Despite the recent clinical success, a rapidly increasing number of patients suffer from ICI-induced cardiotoxicity with often fatal outcomes, nonspecific symptoms and uninvestigated underlying pathological mechanisms. Therefore, this study explored metabolic, muscle wasting, and autophagic pathways and their roles in ICI-induced cardiac remodeling and dysfunction. Female C57BL\/6 wildtype and LC3 transgenic (autophagy reporter) mice were randomly assigned to control (CON) and ICI-treated (ICI) groups. Mice underwent 4 weeks of ICI treatment (200\u00a0\u00b5g\/mouse, intraperitoneally, twice\/week). Echocardiography assessed ICI-induced changes in cardiac structure and function. At euthanasia, cardiac tissue was collected for Western Blot analysis of metabolic and muscle wasting signaling pathways and confocal fluorescent microscopy of autophagic flux. ICI treatment reduced tumor burden (-48% mass,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05) and led to significantly decreased cardiac function (-20%) and remodeling, including left ventricular dilation (+\u200950%) and thinning of posterior cardiac walls (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05), indicative of dilated cardiomyopathy. Exploratory protein level analysis revealed dysfunctional muscle wasting (Atrogin1, MuRF1) disrupted AKT and FoxO1 signaling, and altered autophagic flux (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05). In this model, ICI-induced cardiotoxicity was characterized by severe cardiac remodeling and dysfunction, associated with dysfunctional metabolism, muscle wasting, and autophagy. To our knowledge, this is one of the first studies to explore underlying pathological mechanisms, adding novel and impactful insight to the still unclear characteristics of ICI-induced cardiotoxicity and supporting the critical need to further investigate side effects of immunotherapies to optimize clinical treatment of cancers.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-34379-4","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:53:18Z","timestamp":1768485198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anti-PD-1 immune checkpoint inhibitor-induced cardiotoxicity is associated with dysfunctional metabolism, muscle wasting and autophagy"],"prefix":"10.1038","volume":"16","author":[{"given":"Louisa","family":"Tichy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci L.","family":"Parry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"issue":"3","key":"34379_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 71 (3), 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"Cancer J. Clin."},{"key":"34379_CR2","unstructured":"Common Cancer Sites - Cancer Stat Facts & Accessed, S. E. E. R. September 29, (2022). https:\/\/seer.cancer.gov\/statfacts\/html\/common.html"},{"issue":"28","key":"34379_CR3","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1200\/JCO.19.00934","volume":"37","author":"EB Garon","year":"2019","unstructured":"Garon, E. B. et al. Five-Year overall survival for patients with advanced Non\u2013Small-Cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. JCO 37 (28), 2518\u20132527. https:\/\/doi.org\/10.1200\/JCO.19.00934 (2019).","journal-title":"JCO"},{"issue":"5","key":"34379_CR4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/1759-7714.15205","volume":"15","author":"G Punchhi","year":"2024","unstructured":"Punchhi, G., Hussein, A. & Kulkarni, S. Real-world survival outcomes of immunotherapy for advanced non\u2010small cell lung cancer: A single\u2010center retrospective review. Thorac. Cancer. 15 (5), 394\u2013401. https:\/\/doi.org\/10.1111\/1759-7714.15205 (2024).","journal-title":"Thorac. Cancer"},{"key":"34379_CR5","unstructured":"McCluskey, K. Immunotherapy vs. Chemotherapy: What\u2019s the Difference? Cancer Research Institute. Accessed October 17, (2022). https:\/\/www.cancerresearch.org\/en-us\/blog\/june-2016\/difference-cancer-immunotherapy-and-chemotherapy"},{"issue":"21","key":"34379_CR6","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck, M. et al. Five-Year outcomes with pembrolizumab versus chemotherapy for metastatic Non\u2013Small-Cell lung cancer with PD-L1 tumor proportion Score\u2009\u2265\u200950%. J. Clin. Oncol. 39 (21), 2339\u20132349. https:\/\/doi.org\/10.1200\/JCO.21.00174 (2021).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"34379_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","volume":"118","author":"RW Jenkins","year":"2018","unstructured":"Jenkins, R. W., Barbie, D. A. & Flaherty, K. T. Mechanisms of resistance to immune checkpoint inhibitors. Br. J. Cancer. 118 (1), 9\u201316. https:\/\/doi.org\/10.1038\/bjc.2017.434 (2018).","journal-title":"Br. J. Cancer"},{"issue":"2","key":"34379_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/cco.2020.03.08","volume":"9","author":"F Wang","year":"2020","unstructured":"Wang, F. et al. A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China. Chin. Clin. Oncol. 9 (2), 16\u201316. https:\/\/doi.org\/10.21037\/cco.2020.03.08 (2020).","journal-title":"Chin. Clin. Oncol."},{"issue":"10","key":"34379_CR9","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/ejhf.2289","volume":"23","author":"N Rubio-Infante","year":"2021","unstructured":"Rubio-Infante, N. et al. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur. J. Heart Fail. 23 (10), 1739\u20131747. https:\/\/doi.org\/10.1002\/ejhf.2289 (2021).","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"34379_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40959-022-00130-5","volume":"8","author":"ZL Brumberger","year":"2022","unstructured":"Brumberger, Z. L. et al. Cardiotoxicity risk factors with immune checkpoint inhibitors. Cardio-Oncology 8 (1), 3. https:\/\/doi.org\/10.1186\/s40959-022-00130-5 (2022).","journal-title":"Cardio-Oncology"},{"issue":"5","key":"34379_CR11","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.3390\/cancers14051145","volume":"14","author":"C Li","year":"2022","unstructured":"Li, C., Bhatti, S. A. & Ying, J. Immune checkpoint Inhibitors\u2014Associated cardiotoxicity. Cancers 14 (5), 1145. https:\/\/doi.org\/10.3390\/cancers14051145 (2022).","journal-title":"Cancers"},{"key":"34379_CR12","doi-asserted-by":"publisher","first-page":"11456","DOI":"10.3389\/or.2023.11456","volume":"17","author":"RK Paluri","year":"2023","unstructured":"Paluri, R. K., Pulipati, Y. & Regalla, D. K. R. Immune checkpoint inhibitors and their cardiovascular adverse effects. Oncol. Rev. 17, 11456. https:\/\/doi.org\/10.3389\/or.2023.11456 (2023).","journal-title":"Oncol. Rev."},{"issue":"6","key":"34379_CR13","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/bph.15984","volume":"180","author":"T Gergely","year":"2022","unstructured":"Gergely, T. et al. Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin\u201017A as a driver of cardiac dysfunction after anti\u2010PD\u20101 treatment. Br. J. Pharmacol. 180 (6), 740\u2013761. https:\/\/doi.org\/10.1111\/bph.15984 (2022).","journal-title":"Br. J. Pharmacol."},{"issue":"8","key":"34379_CR14","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.cjca.2018.03.012","volume":"34","author":"H Mir","year":"2018","unstructured":"Mir, H. et al. Cardiac complications associated with checkpoint inhibition: A systematic review of the literature in an important emerging area. Can. J. Cardiol. 34 (8), 1059\u20131068. https:\/\/doi.org\/10.1016\/j.cjca.2018.03.012 (2018).","journal-title":"Can. J. Cardiol."},{"key":"34379_CR15","doi-asserted-by":"publisher","first-page":"111708","DOI":"10.1016\/j.biopha.2021.111708","volume":"139","author":"PS Rawat","year":"2021","unstructured":"Rawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S. & Navik, U. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomedicine Pharmacotherapy. 139, 111708. https:\/\/doi.org\/10.1016\/j.biopha.2021.111708 (2021).","journal-title":"Biomedicine Pharmacotherapy"},{"issue":"3","key":"34379_CR16","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1161\/CIR.0000000000001158","volume":"148","author":"D Addison","year":"2023","unstructured":"Addison, D. et al. Equity in Cardio-Oncology care and research: A scientific statement from the American heart association. Circulation 148 (3), 297\u2013308. https:\/\/doi.org\/10.1161\/CIR.0000000000001158 (2023).","journal-title":"Circulation"},{"issue":"1","key":"34379_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41569-022-00807-5","volume":"20","author":"I Fern\u00e1ndez-Ruiz","year":"2023","unstructured":"Fern\u00e1ndez-Ruiz, I. Hormone therapy ameliorates ICI-related myocarditis in mice. Nat. Rev. Cardiol. 20 (1), 4\u20134. https:\/\/doi.org\/10.1038\/s41569-022-00807-5 (2023).","journal-title":"Nat. Rev. Cardiol."},{"issue":"4","key":"34379_CR18","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/SPC.0000000000000233","volume":"10","author":"R Ballar\u00f2","year":"2016","unstructured":"Ballar\u00f2, R., Costelli, P. & Penna, F. Animal models for cancer cachexia. Curr. Opin. Support Palliat. Care. 10 (4), 281\u2013287. https:\/\/doi.org\/10.1097\/SPC.0000000000000233 (2016).","journal-title":"Curr. Opin. Support Palliat. Care"},{"key":"34379_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/rco2.103","author":"L Tichy","year":"2025","unstructured":"Tichy, L. & Parry, T. L. Low-Intensity Exercise Protects Skeletal and Cardiac Muscle Against Cancer-Mediated Muscle Wasting via Regulation of Autophagy and Inflammation.. JCSM Commun. https:\/\/doi.org\/10.1002\/rco2.103 (2025).","journal-title":"JCSM Commun."},{"issue":"8","key":"34379_CR20","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","volume":"23","author":"S Ganatra","year":"2018","unstructured":"Ganatra, S. & Neilan, T. G. Immune checkpoint Inhibitor-Associated myocarditis. Oncologist 23 (8), 879\u2013886. https:\/\/doi.org\/10.1634\/theoncologist.2018-0130 (2018).","journal-title":"Oncologist"},{"issue":"11","key":"34379_CR21","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.120.315894","volume":"128","author":"AH Baik","year":"2021","unstructured":"Baik, A. H. et al. Mechanisms of cardiovascular toxicities associated with immunotherapies. Circ. Res. 128 (11), 1780\u20131801. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.315894 (2021).","journal-title":"Circ. Res."},{"issue":"10124","key":"34379_CR22","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi, J. J., Salem, J. E., Sosman, J. A., Lebrun-Vignes, B. & Johnson, D. B. Rapid increase in reporting of fatal immune checkpoint inhibitor associated myocarditis. Lancet 391 (10124), 933. https:\/\/doi.org\/10.1016\/S0140-6736(18)30533-6 (2018).","journal-title":"Lancet"},{"issue":"4","key":"34379_CR23","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1089\/mab.2021.0068","volume":"41","author":"MT Bu","year":"2022","unstructured":"Bu, M. T., Yuan, L., Klee, A. N. & Freeman, G. J. A comparison of murine PD-1 and PD-L1 monoclonal antibodies. Monoclon. Antib. Immunodiagn Immunother. 41 (4), 202\u2013209. https:\/\/doi.org\/10.1089\/mab.2021.0068 (2022).","journal-title":"Monoclon. Antib. Immunodiagn Immunother"},{"issue":"7","key":"34379_CR24","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.ccell.2022.05.006","volume":"40","author":"E Kurz","year":"2022","unstructured":"Kurz, E. et al. Exercise-induced engagement of the IL-15\/IL-15R\u03b1 axis promotes anti-tumor immunity in pancreatic cancer. Cancer Cell. 40 (7), 720\u2013737e5. https:\/\/doi.org\/10.1016\/j.ccell.2022.05.006 (2022).","journal-title":"Cancer Cell."},{"key":"34379_CR25","doi-asserted-by":"publisher","first-page":"OF1","DOI":"10.1158\/2326-6066.CIR-22-0465","volume":"29","author":"H Savage","year":"2023","unstructured":"Savage, H. et al. Aerobic exercise alters the melanoma microenvironment and modulates ERK5 S496 phosphorylation. Cancer Immunol. Research Published Online June. 29, OF1\u2013OF16. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0465 (2023).","journal-title":"Cancer Immunol. Research Published Online June"},{"key":"34379_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1385\/0-89603-268-X:9","volume":"32","author":"NJ Kruger","year":"1994","unstructured":"Kruger, N. J. The Bradford method for protein quantitation. Methods Mol. Biol. 32, 9\u201315. https:\/\/doi.org\/10.1385\/0-89603-268-X:9 (1994).","journal-title":"Methods Mol. Biol."},{"issue":"7470","key":"34379_CR27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nature12639","volume":"502","author":"O Pampliega","year":"2013","unstructured":"Pampliega, O. et al. Functional interaction between autophagy and ciliogenesis. Nature 502 (7470), 194\u2013200. https:\/\/doi.org\/10.1038\/nature12639 (2013).","journal-title":"Nature"},{"issue":"5","key":"34379_CR28","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/cncr.32624","volume":"126","author":"B Youn","year":"2020","unstructured":"Youn, B., Trikalinos, N. A., Mor, V., Wilson, I. B. & Dahabreh, I. J. Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non-small cell lung cancer. Cancer 126 (5), 978\u2013985. https:\/\/doi.org\/10.1002\/cncr.32624 (2020).","journal-title":"Cancer"},{"key":"34379_CR29","unstructured":"Immunomodulators Checkpoint Inhibitors, Cytokines, Agonists, Adjuvants. Cancer Research Institute. Accessed September 24, (2022). https:\/\/www.cancerresearch.org\/en-us\/immunotherapy\/treatment-types\/immunomodulators-checkpoint-inhibitors"},{"issue":"7","key":"34379_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11912-021-01070-6","volume":"23","author":"RP Patel","year":"2021","unstructured":"Patel, R. P. et al. Cardiotoxicity of immune checkpoint inhibitors. Curr. Oncol. Rep. 23 (7), 79. https:\/\/doi.org\/10.1007\/s11912-021-01070-6 (2021).","journal-title":"Curr. Oncol. Rep."},{"issue":"18","key":"34379_CR31","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint Blockade. N Engl. J. Med. 375 (18), 1749\u20131755. https:\/\/doi.org\/10.1056\/NEJMoa1609214 (2016).","journal-title":"N Engl. J. Med."},{"key":"34379_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.1087287","author":"A Xu","year":"2022","unstructured":"Xu, A. et al. Early detection of immune checkpoint inhibitor-related subclinical cardiotoxicity: A pilot study by using speckle tracking imaging and three-dimensional echocardiography. Front. Cardiovasc. Med. https:\/\/doi.org\/10.3389\/fcvm.2022.1087287 (2022).","journal-title":"Front. Cardiovasc. Med."},{"issue":"8","key":"34379_CR33","first-page":"3548","volume":"12","author":"Y Li","year":"2022","unstructured":"Li, Y., Liu, P. J., Zhang, Z. L. & Wang, Y. N. Cardiac imaging techniques for the assessment of immune checkpoint inhibitor-induced cardiotoxicity and their potential clinical applications. Am. J. Cancer Res. 12 (8), 3548\u20133560 (2022).","journal-title":"Am. J. Cancer Res."},{"key":"34379_CR34","doi-asserted-by":"publisher","unstructured":"Echocardiographic findings in fulminant and acute myocarditis | Journal of the American College of Cardiology. Accessed November 25. https:\/\/www.jacc.org\/doi\/full\/ (2024). https:\/\/doi.org\/10.1016\/S0735-1097%2800%2900690-2","DOI":"10.1016\/S0735-1097%2800%2900690-2"},{"issue":"9","key":"34379_CR35","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40264-023-01320-5","volume":"46","author":"E Raschi","year":"2023","unstructured":"Raschi, E. et al. Cardiovascular toxicity of immune checkpoint inhibitors: A guide for clinicians. Drug Saf. 46 (9), 819\u2013833. https:\/\/doi.org\/10.1007\/s40264-023-01320-5 (2023).","journal-title":"Drug Saf."},{"issue":"5","key":"34379_CR36","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.3892\/or.2017.5542","volume":"37","author":"Y Belloum","year":"2017","unstructured":"Belloum, Y., Rannou-Bekono, F. & Favier, F. B. Cancer-induced cardiac cachexia: pathogenesis and impact of physical activity (Review). Oncol. Rep. 37 (5), 2543\u20132552. https:\/\/doi.org\/10.3892\/or.2017.5542 (2017).","journal-title":"Oncol. Rep."},{"issue":"4","key":"34379_CR37","doi-asserted-by":"publisher","first-page":"H466","DOI":"10.1152\/ajpheart.00720.2015","volume":"310","author":"KT Murphy","year":"2016","unstructured":"Murphy, K. T. The pathogenesis and treatment of cardiac atrophy in cancer cachexia. Am. J. Physiol. Heart Circ. Physiol. 310 (4), H466\u2013H477. https:\/\/doi.org\/10.1152\/ajpheart.00720.2015 (2016).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"5","key":"34379_CR38","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1002\/ehf2.14045","volume":"9","author":"A Lalario","year":"2022","unstructured":"Lalario, A. et al. Clinical characterization and natural history of chemotherapy-induced dilated cardiomyopathy. ESC Heart Fail. 9 (5), 3052\u20133059. https:\/\/doi.org\/10.1002\/ehf2.14045 (2022).","journal-title":"ESC Heart Fail."},{"key":"34379_CR39","doi-asserted-by":"publisher","unstructured":"Heat Shock Protein 20 Interacting With Phosphorylated Akt Reduces Doxorubicin-Triggered Oxidative Stress and Cardiotoxicity | Circulation Research. Accessed November 26. https:\/\/www.ahajournals.org\/doi\/full\/ (2024). https:\/\/doi.org\/10.1161\/CIRCRESAHA.108.182832","DOI":"10.1161\/CIRCRESAHA.108.182832"},{"issue":"2","key":"34379_CR40","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00441-012-1475-8","volume":"350","author":"P Dimitrakis","year":"2012","unstructured":"Dimitrakis, P., Romay-Ogando, M. I., Timolati, F., Suter, T. M. & Zuppinger, C. Effects of doxorubicin cancer therapy on autophagy and the ubiquitin-proteasome system in long-term cultured adult rat cardiomyocytes. Cell. Tissue Res. 350 (2), 361\u2013372. https:\/\/doi.org\/10.1007\/s00441-012-1475-8 (2012).","journal-title":"Cell. Tissue Res."},{"issue":"4","key":"34379_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-021-03614-x","volume":"12","author":"E Christidi","year":"2021","unstructured":"Christidi, E. & Brunham, L. R. Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell. Death Dis. 12 (4), 1\u201315. https:\/\/doi.org\/10.1038\/s41419-021-03614-x (2021).","journal-title":"Cell. Death Dis."},{"issue":"6","key":"34379_CR42","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1002\/ehf2.13065","volume":"7","author":"W Yu","year":"2020","unstructured":"Yu, W., Chen, C. & Cheng, J. The role and molecular mechanism of FoxO1 in mediating cardiac hypertrophy. ESC Heart Fail. 7 (6), 3497\u20133504. https:\/\/doi.org\/10.1002\/ehf2.13065 (2020).","journal-title":"ESC Heart Fail."},{"issue":"1","key":"34379_CR43","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCRESAHA.107.164186","volume":"102","author":"KN Papanicolaou","year":"2008","unstructured":"Papanicolaou, K. N., Izumiya, Y. & Walsh, K. Forkhead transcription factors and cardiovascular biology. Circul. Res. 102 (1), 16\u201331. https:\/\/doi.org\/10.1161\/CIRCRESAHA.107.164186 (2008).","journal-title":"Circul. Res."},{"issue":"9","key":"34379_CR44","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.tem.2019.07.009","volume":"30","author":"Z Cheng","year":"2019","unstructured":"Cheng, Z. The FoxO\u2013Autophagy axis in health and disease. Trends Endocrinology Metabolism. 30 (9), 658\u2013671. https:\/\/doi.org\/10.1016\/j.tem.2019.07.009 (2019).","journal-title":"Trends Endocrinology Metabolism"},{"issue":"10","key":"34379_CR45","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.metabol.2014.06.012","volume":"63","author":"J Liu","year":"2014","unstructured":"Liu, J. et al. Acetylated FoxO1 mediates high-glucose induced autophagy in H9c2 cardiomyoblasts: regulation by a polyphenol -(\u2013)-epigallocatechin-3-gallate. Metabolism - Clinical Experimental. 63 (10), 1314\u20131323. https:\/\/doi.org\/10.1016\/j.metabol.2014.06.012 (2014).","journal-title":"Metabolism - Clinical Experimental"},{"key":"34379_CR46","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.atherosclerosis.2016.04.001","volume":"249","author":"BA Kappel","year":"2016","unstructured":"Kappel, B. A. et al. Posttranslational modulation of FoxO1 contributes to cardiac remodeling in post-ischemic heart failure. Atherosclerosis 249, 148\u2013156. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.04.001 (2016).","journal-title":"Atherosclerosis"},{"issue":"7","key":"34379_CR47","doi-asserted-by":"publisher","first-page":"988","DOI":"10.4161\/auto.6.7.13289","volume":"6","author":"Y Zhao","year":"2010","unstructured":"Zhao, Y. et al. Anti-neoplastic activity of the cytosolic FoxO1 results from autophagic cell death. Autophagy 6 (7), 988\u2013990. https:\/\/doi.org\/10.4161\/auto.6.7.13289 (2010).","journal-title":"Autophagy"},{"issue":"13","key":"34379_CR48","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1074\/jbc.RA119.011571","volume":"295","author":"P Xia","year":"2020","unstructured":"Xia, P. et al. Doxorubicin induces cardiomyocyte apoptosis and atrophy through cyclin-dependent kinase 2\u2013mediated activation of forkhead box O1. J. Biol. Chem. 295 (13), 4265\u20134276. https:\/\/doi.org\/10.1074\/jbc.RA119.011571 (2020).","journal-title":"J. Biol. Chem."},{"key":"34379_CR49","doi-asserted-by":"publisher","first-page":"177027","DOI":"10.1016\/j.ejphar.2024.177027","volume":"984","author":"PKN Alves","year":"2024","unstructured":"Alves, P. K. N., Cruz, A., Adams, V., Moriscot, A. S. & Labeit, S. Small-molecule mediated MuRF1 Inhibition protects from doxorubicin-induced cardiac atrophy and contractile dysfunction. Eur. J. Pharmacol. 984, 177027. https:\/\/doi.org\/10.1016\/j.ejphar.2024.177027 (2024).","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"34379_CR50","doi-asserted-by":"publisher","first-page":"e005234","DOI":"10.1161\/CIRCHEARTFAILURE.118.005234","volume":"12","author":"MS Willis","year":"2019","unstructured":"Willis, M. S. et al. Doxorubicin exposure causes subacute cardiac atrophy dependent upon the striated muscle-specific ubiquitin ligase muscle ring Finger-1. Circ. Heart Fail. 12 (3), e005234. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.118.005234 (2019).","journal-title":"Circ. Heart Fail."},{"key":"34379_CR51","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.yjmcc.2013.11.007","volume":"71","author":"DL Li","year":"2014","unstructured":"Li, D. L. & Hill, J. A. Cardiomyocyte autophagy and cancer chemotherapy. J. Mol. Cell. Cardiol. 71, 54\u201361. https:\/\/doi.org\/10.1016\/j.yjmcc.2013.11.007 (2014).","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"8","key":"34379_CR52","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.1161\/CIRCRESAHA.121.319104","volume":"129","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. atg7-Based autophagy activation reverses Doxorubicin-Induced cardiotoxicity. Circul. Res. 129 (8), e166\u2013e182. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.319104 (2021).","journal-title":"Circul. Res."},{"key":"34379_CR53","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.bcp.2018.02.025","volume":"150","author":"J Gu","year":"2018","unstructured":"Gu, J. et al. Resveratrol suppresses doxorubicin-induced cardiotoxicity by disrupting E2F1 mediated autophagy Inhibition and apoptosis promotion. Biochem. Pharmacol. 150, 202\u2013213. https:\/\/doi.org\/10.1016\/j.bcp.2018.02.025 (2018).","journal-title":"Biochem. Pharmacol."},{"issue":"10","key":"34379_CR54","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.3390\/molecules22101589","volume":"22","author":"R Johnson","year":"2017","unstructured":"Johnson, R., Shabalala, S., Louw, J., Kappo, A. P. & Muller, C. J. F. Aspalathin reverts Doxorubicin-Induced cardiotoxicity through increased autophagy and decreased expression of p53\/mTOR\/p62 signaling. Molecules 22 (10), 1589. https:\/\/doi.org\/10.3390\/molecules22101589 (2017).","journal-title":"Molecules"},{"issue":"1","key":"34379_CR55","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijcard.2008.01.043","volume":"134","author":"L Lu","year":"2009","unstructured":"Lu, L. et al. Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure. Int. J. Cardiol. 134 (1), 82\u201390. https:\/\/doi.org\/10.1016\/j.ijcard.2008.01.043 (2009).","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"34379_CR56","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1074\/jbc.M109.070037","volume":"285","author":"S Kobayashi","year":"2010","unstructured":"Kobayashi, S. et al. Transcription factor GATA4 inhibits Doxorubicin-induced autophagy and cardiomyocyte Death *. J. Biol. Chem. 285 (1), 793\u2013804. https:\/\/doi.org\/10.1074\/jbc.M109.070037 (2010).","journal-title":"J. Biol. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34379-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34379-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34379-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T10:13:56Z","timestamp":1769768036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34379-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["34379"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-34379-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The use of animals and all experiments in this study were approved by the IACUC at the University of North Carolina Greensboro.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"4240"}}